Ashte Collins, MD
Nephrology · Washington, DCNPI 1295902625
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $747,703 of the $1,034,498 with a category attached, or 72.3%. 22 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 30.2% of the total. Among nephrology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,678 payments — averaging $616.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$312K
- AstraZeneca$227K
- Travere Therapeutics, Inc.$180K
- Akebia Therapeutics Inc$169K
- Mallinckrodt Enterprises LLC$90K
- Otsuka America Pharmaceutical, Inc.$40K
- plus $16K from 16 others
What the payments were for
- Consulting fees$106,11210%
- Speaking & faculty fees$747,70372%
- Travel & lodging$147,78514%
- Food & beverage$32,2893%
- Education$1200%
- Gifts$410%
- Charitable contribution$4500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 352 | $312,355 |
| AstraZeneca(2 entities) | 313 | $226,803 |
| Travere Therapeutics, Inc. | 321 | $179,771 |
| Akebia Therapeutics Inc | 411 | $169,204 |
| Mallinckrodt Enterprises LLC | 122 | $90,437 |
| Otsuka America Pharmaceutical, Inc. | 49 | $40,191 |
| ANI Pharmaceuticals, Inc. | 16 | $4,594 |
| Fresenius USA Marketing, Inc. | 28 | $4,438 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,700 |
| Novo Nordisk | 4 | $2,291 |
| Vifor Pharma, Inc. | 9 | $402 |
| Amgen | 15 | $380 |
| Ardelyx, Inc. | 9 | $266 |
| GSK | 10 | $223 |
| Aurinia Pharma U.S., Inc. | 6 | $162 |
| Calliditas Therapeutics US Inc. | 4 | $94 |
| Bayer | 2 | $53 |
| Lilly USA, LLC | 2 | $44 |
| Baxter Healthcare | 1 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,034,498 in reported general payments places this provider in the 95th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 123 | $120,771 |
| VelphoroSucroferric Oxyhydroxide | 23 | $107,117 |
| Sevelamer Carbonate | 95 | $44,825 |
| LokelmaSodium Zirconium Cyclosilicate | 45 | $40,347 |
| JardianceEmpagliflozin | 46 | $31,396 |
| EliquisApixaban | 31 | $24,040 |
| JanuviaSitagliptin Phosphate | 23 | $20,392 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $18,087 |
| KerendiaFinerenone | 12 | $10,027 |
| Clonidine | 32 | $4,243 |
| Nifedipine ErNifedipine | 102 | $3,598 |
| Candesartan Cilexetil | 43 | $3,483 |
| Calcium Acetate | 22 | $3,317 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,548 |
| Midodrine Hcl | 19 | $1,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $226,803 | $161,118168 claims |
| Fresenius USA Marketing, Inc.Velphoro | $4,438 | $107,11723 claims |
| BayerKerendia | $53 | $10,02712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $4,594 | $80126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 nephrology providers in District of Columbia.
Other nephrology in Washington
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
- Antonina KolesnikovaWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.